In this study, we employed an unbiased chemogenomic screening approach in an isogenic model of FAK-kinase-deficient (KD) and FAK-wild-type (WT) expressing GBM cells to identify drug combinations that could potentially synergize with the depletion of FAK kinase activity. The gene discussed is PTK2; the disease is glioblastoma.